trial

Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

NCTId NCT07363577
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 456 (estimated)
Sponsored by LB Pharmaceuticals Inc.
Primary completion 2027-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
456 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Sequential
Masking
Quadruple
Start
2026-03-25
Primary completion
2027-06
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
LB-102

Sponsors

LB Pharmaceuticals Inc.Lead Sponsor

Sites

13 total
Bentonville, United StatesLittle Rock, United StatesLittle Rock, United StatesCulver City, United StatesGarden Grove, United StatesLemon Grove, United StatesRiverside, United StatesBoynton Beach, United StatesMiami Lakes, United StatesSnellville, United StatesChicago, United StatesSt Louis, United States

Linked catalysts

2
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizoph — primary completion2027-06
LB-102 — NOVA-2 (Ph3 schizophrenia) topline data2027-10-01

Facts & assertions

4 sourced
Enrollment
456
Phase
PHASE3
Primary Completion Date
2027-06
Status
RECRUITING
relationships
The graph out of here
drug
LB-102
drug
lead_sponsor
LB Pharmaceuticals Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication